Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
Frontiers in Oncology
|
May 3, 2021
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
Shixue Chen, Zhibo Zhang, Xuan Zheng, et al.
Cancer Medicine
|
May 26, 2018
Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study
Pengfei Cui, Zhefeng Liu, Guoqiang Wang, et al.
Frontiers in Psychiatry
|
September 27, 2024
Causal effects between personality and psychiatric traits and lung cancer: a bidirectional two-sample Mendelian randomization and bibliometric study
Siyuan Chen, Zhijuan Du, Yuhui Qin, et al.
Journal of Hepatocellular Carcinoma
|
November 11, 2020
Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors
Shixue Chen, Ziwei Huang, Wangping Jia, et al.
Therapeutic Advances in Medical Oncology
|
January 6, 2025
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Ming Gao, Xia Zhang, Huan Yan, et al.
Oncotargets and Therapy
|
November 15, 2018
Clinical characterization of <i>ERBB2</i> exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
Zhefeng Liu, Lin Wu, Jun Cao, et al.
Therapeutic Advances in Medical Oncology
|
November 23, 2020
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Zhibo Zhang, Fan Zhang, Fang Yuan, et al.
Translational Lung Cancer Research
|
April 23, 2021
Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors
Shixue Chen, Ruixin Li, Zhibo Zhang, et al.
Signal Transduction and Targeted Therapy
|
February 2, 2026
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial
Fan Zhang, Zhendong Zheng, Hongmei Zhang, et al.
NPJ Precision Oncology
|
August 2, 2025
Integrating genomic and pathological characteristics to enhance prognostic precision in advanced NSCLC
Yingjie Han, Junxun Ma, Zhefeng Liu, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
Frontiers in Oncology
|
May 3, 2021
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
Shixue Chen, Zhibo Zhang, Xuan Zheng, et al.
Cancer Medicine
|
May 26, 2018
Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study
Pengfei Cui, Zhefeng Liu, Guoqiang Wang, et al.
Frontiers in Psychiatry
|
September 27, 2024
Causal effects between personality and psychiatric traits and lung cancer: a bidirectional two-sample Mendelian randomization and bibliometric study
Siyuan Chen, Zhijuan Du, Yuhui Qin, et al.
Journal of Hepatocellular Carcinoma
|
November 11, 2020
Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors
Shixue Chen, Ziwei Huang, Wangping Jia, et al.
Therapeutic Advances in Medical Oncology
|
January 6, 2025
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Ming Gao, Xia Zhang, Huan Yan, et al.
Oncotargets and Therapy
|
November 15, 2018
Clinical characterization of <i>ERBB2</i> exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
Zhefeng Liu, Lin Wu, Jun Cao, et al.
Therapeutic Advances in Medical Oncology
|
November 23, 2020
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Zhibo Zhang, Fan Zhang, Fang Yuan, et al.
Translational Lung Cancer Research
|
April 23, 2021
Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors
Shixue Chen, Ruixin Li, Zhibo Zhang, et al.
Signal Transduction and Targeted Therapy
|
February 2, 2026
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial
Fan Zhang, Zhendong Zheng, Hongmei Zhang, et al.
NPJ Precision Oncology
|
August 2, 2025
Integrating genomic and pathological characteristics to enhance prognostic precision in advanced NSCLC
Yingjie Han, Junxun Ma, Zhefeng Liu, et al.
Page
of 6